Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

In 10% of these tumors, HER3 overexpression was identified and was significantly associated with decreased disease-specific survival. Furthermore, in tumors with normal HER1 and HER2 expression ...

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

Exclusion criteria were the following: non-overexpression of HER2 receptor; cerebral or meningeal metastasis; grade > 1 peripheral neuropathy according to NCI-CTC; severe cardiac dysfunction or ...

In a recent study, the regulatory role of the long noncoding RNA (lncRNA) Gm20257 in pathological cardiac hypertrophy has ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...

College of Advanced Agricultural Sciences, Zhejiang A&F University, Hangzhou, Zhejiang 311300, PR China ...

The overexpression of miR-155-5p in OSCC cells upregulated miR-223-3p significantly (34-fold) compared to the control group. It also led to significant downregulation of the mRNA of P120ctn and ...